Advertisement
LONDON, Nov. 9, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4348819
It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Narcolepsy from 2013-2023. Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. Narcolepsy affects approximately 200,000 Americans and 3 million people worldwide. Narcolepsy is not rare, but it is severely under-recognized and commonly misdiagnosed.
Narcolepsy appears throughout the world but occurrence rates vary among populations. The occurrence rate of narcolepsy is remarkably lower in Israel and quite higher in Japan compared to the United States. In Europe, the occurrence rate is found to be higher in UK and Germany than other European countries.
PROVIGIL by Cephalon, Inc and XYREM by Jazz Pharmaceuticals is the top selling drug for Narcolepsy contributing to majority of the market share. Other drugs are also being used for the treatment of Narcolepsy as secondary indication, but do not have much impact on the overall market size. We have estimated that the worldwide Narcolepsy will increase at a CAGR of 8.48% during the forecast period 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options. - Marketed information including available prescription drugs, its patent and exclusivity details. - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.- It also provides Market size of Narcolepsy for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Download the full report: https://www.reportbuyer.com/product/4348819
About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttps://www.reportbuyer.com
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
Advertisement
It also includes global historical and forecasted epidemiological data for the prevalent, diagnosed and treatable cases of Narcolepsy from 2013-2023. Narcolepsy is a chronic neurological / brain disorder which involves poor control of sleep and wakefulness. Narcolepsy is classically a tetrad of symptoms including EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations. Narcolepsy affects approximately 200,000 Americans and 3 million people worldwide. Narcolepsy is not rare, but it is severely under-recognized and commonly misdiagnosed.
Narcolepsy appears throughout the world but occurrence rates vary among populations. The occurrence rate of narcolepsy is remarkably lower in Israel and quite higher in Japan compared to the United States. In Europe, the occurrence rate is found to be higher in UK and Germany than other European countries.
PROVIGIL by Cephalon, Inc and XYREM by Jazz Pharmaceuticals is the top selling drug for Narcolepsy contributing to majority of the market share. Other drugs are also being used for the treatment of Narcolepsy as secondary indication, but do not have much impact on the overall market size. We have estimated that the worldwide Narcolepsy will increase at a CAGR of 8.48% during the forecast period 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options. - Marketed information including available prescription drugs, its patent and exclusivity details. - The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.- It also provides Market size of Narcolepsy for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Download the full report: https://www.reportbuyer.com/product/4348819
About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttps://www.reportbuyer.com
For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/narcolepsy--market-insights-epidemiology-and-market-forecast-2023-300553647.html
SOURCE ReportBuyer
